Selinexor (Xpovio) for advanced or recurrent endo cancer

"Researchers announce the first results of a Phase 3 clinical study of selinexor as maintenance therapy for advanced or recurrent endometrial cancer following complete or partial response to induction combination platinum/taxane chemotherapy. Compared with the placebo-controlled group, patients receiving the treatment showed a 30% decrease of hazard for progression or death. The effect was most pronounced in the large pre-specified, exploratory subgroup of patients who have a functional p53 gene (p53 wild type), which is in line with the mode of action of selinexor."

...

"Selinexor is already approved for hematological malignancies in Europe and the US."

ENGOT and The GOG Foundation, Inc. (GOG) announce promising first results of new maintenance therapy for advanced or recurrent endometrial cancer